Company Overview and News

 
Thundelarra serves up high-grade gold tasters at Garden Gully project in Western Australia

2018-07-24 proactiveinvestors.com.au
Thundelarra Ltd (ASX:THX) (FRA:TJ3) has received results from drilling at the Crown Prince Prospect that forms part of its Garden Gully Gold Project in Western Australia, finding up to 18.5 g/t gold.
THX

 
Thundelarra aircore results reveal visible supergene gold

2018-06-28 proactiveinvestors.com.au
Thundelarra Ltd (ASX:THX) has received the results from its 274-hole, 14,025-metre aircore drilling program at the Garden Gully gold project in Western Australia.
THX

 
Thundelarra chairman buys one million shares on-market

2018-05-08 proactiveinvestors.com.au
Thundelarra Ltd (ASX:THX) has received a vote of confidence from its chairman Philip Crabb who has purchased another one million shares through on-market trades.
THX

 
Thundelarra’s geophysical survey methods detect gold prospects at Garden Gully

2018-05-01 proactiveinvestors.com.au
Thundelarra Ltd (ASX:THX) has demonstrated that Sub-Audio Magnetics (SAM) geophysical surveys are effective in detecting prospective structures at its Garden Gully Gold Project in Western Australia.
THX

 
Thundelarra enters June quarter with strong cash position to fund drilling

2018-04-24 proactiveinvestors.com.au
Thundelarra Ltd (ASX:THX) completed the March quarter and has therefore entered the current June quarter with $3.68 million in cash and $0.2 million in equity investments.
THX

1
Thundelarra focused on recommencing high-grade gold mining at Garden Gully

2018-04-19 proactiveinvestors.com.au
Thundelarra Ltd (ASX:THX) is focused on exploration at its 100% owned Garden Gully Gold Project located in the Meekatharra area of Western Australia.
SFRRF SNDFY DRM SFR EGS EGDD ESGFF THX

 
Thundelarra's gold exploration "on the cusp of something great"

2018-04-19 proactiveinvestors.com.au
Thundelarra Ltd (ASX:THX) CEO Tony Lofthouse gives Proactive Investors an update on the company’s numerous Australian gold prospects. The main news is from Western Australia where a diamond and RC drilling program is underway in the Crown Prince area of the Garden Gully project near Meekatharra, while low-cost and low-risk exploration is ongoing at Red Bore near Doolgunna.
THX

 
Thundelarra completes 14,000-metre aircore drill program at Garden Gully

2018-04-18 proactiveinvestors.com.au
Thundelarra Ltd (ASX:THX) has completed its 274-hole, 14,025-metre aircore drill program at its flagship Garden Gully Gold Project in Western Australia.
DRM THX

 
Thundelarra commences follow-up drill program testing for gold extensions

2018-04-16 proactiveinvestors.com.au
Thundelarra Ltd (ASX:THX) has commenced follow-up drilling at the Crown Prince prospect within its flagship 100% owned Garden Gully Gold Project in Western Australia.
THX

 
Thundelarra commences follow-up drill program testing for extensions

2018-04-16 proactiveinvestors.com.au
Thundelarra Ltd (ASX:THX) has commenced follow-up drilling at the Crown Prince prospect within its flagship 100% owned Garden Gully Gold Project in Western Australia.
THX

 
Thundelarra uses aircore drilling to generate further gold targets at Garden Gully

2018-03-27 proactiveinvestors.com.au
Thundelarra Ltd (ASX:THX) is undertaking aircore drilling at the Garden Gully Gold Project in Western Australia to test for near-surface extensions of mineralised targets.
THX

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...